Prognosis
How an HIV Trial Triggered a 667% Jump in Australian Penny Stock
This article is for subscribers only.
The name is Biotron Ltd., and before its five-day 667 percent rally, it had a share price of just 2 Australian cents.
The Sydney-based drug company with just five full-time employees last week announced the “successful” outcome of a phase-two trial of BIT225 HIV-1 drug and retail investors have been lapping it up. The company said its therapy suppressed the HIV virus more than current antiretrovirals.